USANA Health Sciences (USNA) Expected to Announce Quarterly Earnings on Tuesday

USANA Health Sciences (NYSE:USNA) is anticipated to issue its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of $0.11 per share and revenue of $217.42 million for the quarter. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. Interested persons can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 11:00 AM ET.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, August 4th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.50). USANA Health Sciences had a positive return on equity of 3.41% and a negative net margin of 2.43%. The firm had revenue of $223.27 million during the quarter, compared to the consensus estimate of $235.00 million. On average, analysts expect USANA Health Sciences to post $0.76 EPS for the current fiscal year and $1.77 EPS for the next fiscal year.

USANA Health Sciences Stock Down 0.5%

NYSE:USNA opened at $14.27 on Friday. The company’s 50 day moving average price is $14.55 and its 200-day moving average price is $18.13. USANA Health Sciences has a 52 week low of $12.57 and a 52 week high of $23.59. The stock has a market cap of $263.71 million, a price-to-earnings ratio of -11.79, a PEG ratio of 1.57 and a beta of 0.68.

Analyst Ratings Changes

A number of equities analysts recently weighed in on USNA shares. Wall Street Zen lowered shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a research report on Monday, September 21st. Finally, Zacks Research upgraded USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 5th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, USANA Health Sciences currently has an average rating of “Reduce”.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.